What is the recommended dosing for Brio Ellipta (fluticasone furoate and vilanterol) inhaler?

Breo Ellipta (Fluticasone Furoate/Vilanterol) Dosing Recommendations

The recommended dosage of Breo Ellipta for COPD is 100/25 mcg (containing fluticasone furoate 100 mcg and vilanterol 25 mcg), administered as 1 actuation once daily by oral inhalation. 1

Dosing Guidelines for Different Conditions

For COPD:

• Dose: 100/25 mcg once daily
• Administration: One inhalation via the Ellipta dry powder inhaler
• Timing: Should be used at the same time every day
• Duration: Long-term maintenance therapy

For Asthma (if relevant):

• Adults (18+ years): 100/25 mcg or 200/25 mcg once daily
• Adolescents (12-17 years): 100/25 mcg once daily
• Children (5-11 years): 50/25 mcg once daily

Administration Instructions

1. Administer at the same time every day
2. Do not use more than once every 24 hours
3. After inhalation, rinse mouth with water (without swallowing) to reduce risk of oral candidiasis
4. If shortness of breath occurs between doses, use a short-acting beta2-agonist (rescue inhaler) for immediate relief

Clinical Efficacy

Breo Ellipta has demonstrated significant efficacy in COPD management:

• Improves lung function more effectively than either component alone 2
• Reduces exacerbations more effectively than vilanterol monotherapy 2
• Shows comparable efficacy to twice-daily ICS/LABA combinations in terms of lung function and health status outcomes 3
• Provides rapid and sustained bronchodilation over 24 weeks 4, 5

Important Considerations and Precautions

• Not for acute bronchospasm: Breo Ellipta is NOT indicated for the relief of acute bronchospasm 1
• Pneumonia risk: Long-term use is associated with increased risk of pneumonia, as with other inhaled corticosteroids 6
• Contraindications:
  • Primary treatment of status asthmaticus or other acute episodes of COPD
  • Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, vilanterol, or excipients 1

Advantages of Breo Ellipta

• Once-daily dosing may improve treatment adherence compared to twice-daily alternatives 6
• Convenient delivery system (Ellipta dry powder inhaler)
• Comparable efficacy to established twice-daily ICS/LABA combinations 3

Common Pitfalls to Avoid

1. Exceeding recommended frequency: Never administer more than once daily
2. Using for acute symptoms: Not appropriate for rescue therapy
3. Stopping abruptly: Should be used consistently as maintenance therapy
4. Forgetting post-inhalation mouth rinse: Important to prevent oral candidiasis
5. Poor inhaler technique: Ensure proper training on Ellipta device use

The once-daily dosing regimen of Breo Ellipta offers a convenient option for COPD maintenance therapy with efficacy comparable to twice-daily alternatives, potentially improving treatment adherence in patients with chronic respiratory conditions.